Effect of Hypocalcemia on the Outcome of Elderly Major Trauma Patients With Trauma-induced Coagulopathy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hanzhou, Zhejiang, China, 310009
- Recruiting
- SAHZU
-
Contact:
- Yongan Xu
- Phone Number: 13757164833
- Email: xuyongan2000@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age≥65 years old
- history of trauma
Exclusion Criteria:
- previous anticoagulants or antiplatelet medication;
- Coagulopathy caused by previous underlying diseases;
- Blood products transfused before admission;
- Cardiac arrest on admission;
- Malignant tumor;
- Data incomplete
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
trauma induced coagulopathy
patients with INR>1.2
|
hypocalcemia or normocalcemia
|
|
non-trauma induced coagulopathy
patients with INR≤1.2
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Internationalized Normalized Ratio (INR)
Time Frame: 24 hour
|
coagulation function :Internationalized Normalized Ratio (INR)
|
24 hour
|
|
Activated Partial Thromboplastin Time (APTT)
Time Frame: 24 hour
|
coagulation function : Activated Partial Thromboplastin Time (APTT)
|
24 hour
|
|
Prothrombin Time (PT)
Time Frame: 24 hour
|
coagulation function : Prothrombin Time (PT)
|
24 hour
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood products rate
Time Frame: through study completion, an average of 1 week
|
the rate of Blood products use
|
through study completion, an average of 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: yongan xu, doctor, Department of Emergency medicine,Second Affiliated Hospitalof Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-822
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.